



## Merus Labs Appoints Two New Senior Executives

---

**TORONTO, ONTARIO – June 30, 2016** – Merus Labs International Inc. (“Merus” or the “Company”) (TSX: MSL, NASDAQ: MSLI) is pleased to announce two key additions to its executive leadership team effective July 1, 2016.

**Dr. Michael Bumby** is appointed Chief Financial Officer (CFO) succeeding Mr. Andrew Patient who has decided to leave the Company to pursue other opportunities. Mr. Patient will remain with Merus Labs for a period of time to ensure a smooth transition. Dr. Bumby was most recently the CFO of Acerus Pharmaceuticals Inc. Dr. Bumby had a diverse 14 year career at Eli Lilly, including Corporate Finance & Investment Banking at Lilly’s global headquarters in Indianapolis leading international business development activities for early and late stage assets, and regional CFO for Lilly’s Czech and Slovak subsidiaries based in Prague. He holds a Doctor of Veterinary Medicine from the University of Guelph and an MBA from the University of Toronto.

To further strengthen our executive leadership team, the Company is also pleased to appoint **Mr. Frank Fokkinga** as Vice President, Global Regulatory Affairs, Quality and Compliance. Based in Zurich, Switzerland, Mr. Fokkinga has over 30 years of pharmaceutical experience in regulatory affairs, global market research, business development and market access. Mr. Fokkinga has a proven history of success with gaining product approval and market access across Europe in a variety of therapeutic categories. Mr. Fokkinga previously served as Vice President, International Regulatory Affairs at Takeda Pharmaceuticals. He also progressed a variety of leadership roles at Genzyme (now part of Sanofi) and Organon (now part of Merck).

“The Board of Directors and I are delighted to welcome Dr. Bumby and Mr. Fokkinga to the Merus Labs executive leadership team,” said Barry Fishman, Chief Executive Officer. “Their enthusiasm, entrepreneurial spirit and expertise is expected to accelerate the execution of our growth strategy.” Mr. Fishman added, “I would also like to take this opportunity to thank Mr. Patient for his important role in the Company’s growth and his contributions over the years.”

### About Merus Labs

Merus Labs is a specialty pharmaceutical company focused on acquiring and optimizing established and growth products. The Company leverages its expertise and commercial platform in Europe, Canada and select other markets to deliver value.

### Contact Information

Phone: [\(416\) 593-3725](tel:4165933725)

Email: [info@meruslabs.com](mailto:info@meruslabs.com)